Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. director Mahkam Zanganeh reported receiving two stock option grants. The options cover 14,504 and 30,000 shares of common stock at an exercise price of $26.89 per share and expire on June 11, 2036.

The 14,504-share option vests in equal monthly installments over one year starting on July 11, 2026, subject to continued service. The 30,000-share option vests in equal quarterly installments over one year starting on September 5, 2026. These are compensation-related awards, not open-market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zanganeh Mahkam

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--
Grant/Award	Stock Option (right to buy)	14,504	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

Key Figures

Option grant size 1: 14,504 options Option grant size 2: 30,000 options Exercise price: $26.89 per share +3 more

6 metrics

Option grant size 1 14,504 options Stock option grant to director Mahkam Zanganeh

Option grant size 2 30,000 options Second stock option grant to Mahkam Zanganeh

Exercise price $26.89 per share Exercise price for both option grants

Expiration date June 11, 2036 Expiration for both stock option grants

Monthly vesting start July 11, 2026 First vesting date for 14,504-share grant

Quarterly vesting start September 5, 2026 First vesting date for 30,000-share grant

Key Terms

Stock Option (right to buy), exercise price, vesting, equal monthly installments, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 26.8900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option will vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

equal monthly installments financial

"will vest in equal monthly installments over a one-year period"

equal quarterly installments financial

"will vest in equal quarterly installments over a one-year period"

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zanganeh Mahkam

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.89	06/11/2026		A		30,000		(1)	06/11/2036	Common Stock	30,000	$0	30,000	D
Stock Option (right to buy)	$26.89	06/11/2026		A		14,504		(2)	06/11/2036	Common Stock	14,504	$0	14,504	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.

2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PULSE BIOSCIENCES (PLSE) director Mahkam Zanganeh report on this Form 4?

Mahkam Zanganeh reported receiving two stock option grants as compensation. The awards cover 14,504 and 30,000 shares of common stock, giving the right to buy shares at a fixed exercise price of $26.89 per share until June 11, 2036.

How many stock options were granted to Mahkam Zanganeh at PULSE BIOSCIENCES (PLSE)?

Two separate option grants were reported for Mahkam Zanganeh. One covers 14,504 shares and the other covers 30,000 shares of PULSE BIOSCIENCES common stock, both structured as stock options with a fixed exercise price and defined vesting schedules over one-year periods.

What is the exercise price and expiration date of the PLSE options granted to Mahkam Zanganeh?

Both option grants have an exercise price of $26.89 per share and share the same expiration date. The options expire on June 11, 2036, giving Zanganeh the right to purchase the underlying common shares any time after vesting and before expiration.

How do the 14,504-share stock options granted by PULSE BIOSCIENCES (PLSE) vest?

The 14,504-share option grant vests in equal monthly installments over one year. Vesting begins on July 11, 2026, and each monthly tranche requires Mahkam Zanganeh to remain in service through the applicable vesting date to earn the corresponding portion.

What is the vesting schedule for the 30,000-share PLSE option grant to Mahkam Zanganeh?

The 30,000-share option grant vests in equal quarterly installments over one year. The first quarterly vesting date is September 5, 2026. Continued service through each quarterly date is required for Zanganeh to earn the related portion of the option award.

Does this PLSE Form 4 show Mahkam Zanganeh buying or selling common stock on the market?

No, the filing reports compensation-related stock option grants, not market trades. The transactions are coded as awards, giving Zanganeh future rights to purchase shares at $26.89 per share, rather than immediate open-market purchases or sales of common stock.